loader
Please Wait
Applying Filters...

Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Trandolapril Mixture With Verapamil, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Trandolapril Mixture With Verapamil

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    PharmaCompass

    Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    2D Structure
    1. Also known as: Trandolapril mixture with verapamil, Verapamil mixture with trandolapril, Trandolapril/verapamil hydrochloride er, Trandolapril mixture with verapamil hcl, Trandolapril plus verapamil hydrochloride, Trandolapril-verapamil hydrochloride mixt.
    Molecular Formula
    C51H73ClN4O9
    Molecular Weight
    921.6  g/mol
    InChI Key
    PPAGZPRHIOKKLV-WDFOJNLTSA-N
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid;2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile;hydrochloride
    2.1.2 InChI
    InChI=1S/C27H38N2O4.C24H34N2O5.ClH/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6;1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29;/h9-12,17-18,20H,8,13-16H2,1-7H3;4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29);1H/t;16-,18+,19-,20-,21-;/m.0./s1
    2.1.3 InChI Key
    PPAGZPRHIOKKLV-WDFOJNLTSA-N
    2.1.4 Canonical SMILES
    CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCCC3CC2C(=O)O.CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl
    2.1.5 Isomeric SMILES
    CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(=O)O.CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl
    2.2 Synonyms
    2.2.1 Depositor-Supplied Synonyms

    1. Trandolapril Mixture With Verapamil

    2. Verapamil Mixture With Trandolapril

    3. Trandolapril/verapamil Hydrochloride Er

    4. Trandolapril Mixture With Verapamil Hcl

    5. Trandolapril Plus Verapamil Hydrochloride

    6. Trandolapril-verapamil Hydrochloride Mixt.

    7. Trandolapril Mixture With Verapamil Hydrochloride

    8. Schembl2526928

    9. 146994-90-3

    10. 1h-indole-2-carboxylic Acid, 1-((2s)-2-(((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2s,3ar,7as)-, Mixt. With Alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile Monohydrochloride

    2.3 Create Date
    2008-07-11
    3 Chemical and Physical Properties
    Molecular Weight 921.6 g/mol
    Molecular Formula C51H73ClN4O9
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count23
    Exact Mass920.5066076 g/mol
    Monoisotopic Mass920.5066076 g/mol
    Topological Polar Surface Area160 Ų
    Heavy Atom Count65
    Formal Charge0
    Complexity1240
    Isotope Atom Count0
    Defined Atom Stereocenter Count5
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 1  
    Drug NameTRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
    Active IngredientTRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE
    CompanyGLENMARK GENERICS (Application Number: A079135)

    5 Pharmacology and Biochemistry
    5.1 FDA Pharmacological Classification
    5.1.1 Pharmacological Classes
    Angiotensin-converting Enzyme Inhibitors [MoA]; Calcium Channel Antagonists [MoA]; Calcium Channel Blocker [EPC]; Cytochrome P450 3A Inhibitors [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Angiotensin Converting Enzyme Inhibitor [EPC]
    Post Enquiry
    POST ENQUIRY